Reactivation of Tuberculosis in Patients with Ankylosing Spondylitis on Tofacitinib Therapy

JOURNAL TITLE: AMEI's Current Trends in Diagnosis & Treatment

Author
1. Manavdeep Kaur
2. Parminder Singh
ISSN
2582-4260
DOI
10.5005/jp-journals-10055-0140
Volume
6
Issue
2
Publishing Year
2022
Pages
2
Author Affiliations
    1. Department of Endocrinology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
    1. Department of Medicine, Sri Guru Ram Das University of Health Sciences, Sri Amritsar, Punjab, India
  • Article keywords
    Ankylosing spondylitis, Pott\'s spine, Tofacitinib

    Abstract

    Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton and peripheral joints. It is immune-mediated common in the second and third decades having symptoms such as sacroiliitis, synovitis, and difficulty in movement of the spine. It is treated with non-steroidal anti-inflammatory drugs (NSAIDs), JAK 2 inhibitors, and other biologicals such as infliximab and etanercept. This is the case report of a 24-year-old male student who presented with lower backache, and morning stiffness which improved with activity. On investigation, his HLA B 27 was positive and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were raised. He was treated with tofacitinib for 1 year, later he developed pott\'s spine as its side effect. This case report represents the rare side effect of tofacitinib as pott\'s spine.

    © 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved